Application of diosgenin and derivative thereof for preparing tumor chemotherapy sensitization medicines

A technology of diosgenin and derivatives is applied in the application field of preparing tumor chemotherapy sensitizing drugs, and can solve the problem that diosgenin is not widely used and the like

Active Publication Date: 2012-05-30
NORTHEAST NORMAL UNIVERSITY
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current clinical application of diosgenin is not extensive.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of diosgenin and derivative thereof for preparing tumor chemotherapy sensitization medicines
  • Application of diosgenin and derivative thereof for preparing tumor chemotherapy sensitization medicines
  • Application of diosgenin and derivative thereof for preparing tumor chemotherapy sensitization medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Obtaining Diosgenin and Its Derivatives

[0058] Diosgenin and its derivatives can be purchased from commercial products or prepared by the following methods:

[0059] For the preparation method of diosgenin, see patent 200610040991.1 (Tang Qinghua, Yao Yunshan, Tang Xiaohui. A method for extracting cantharidin. Intellectual Property Office of the People's Republic of China).

[0060] Diosgenin and its derivatives can be purchased from commercial products or prepared by the following methods:

[0061] For the preparation method of diosgenin, see patent 200610028164.0 (Zhu Xian, Guo Xiaoya, Wang Zhenwu. Method for preparing diosgenin by super (near) critical water hydrolysis. Intellectual Property Office of the People's Republic of China).

[0062] For the preparation method of dioscin, see patent 02146284 (Zhao Quancheng, He Yufang, Liu Wei. Preparation method of dioscin, pharmaceutical preparation and its new medical application. Intellectual Property Office of the ...

Embodiment 2

[0065] Induction of multidrug resistant cell lines

[0066] Human liver cancer cell HepG2, human leukemia cell K562, human colon cancer cell LoVo cell, human breast cancer cell MCF-7, human lung cancer cell A549, human gastric cancer cell SGC7901, ovarian cancer SKOV3, cervical cancer Hela, kidney cancer 786-0 or prostate cancer PC-3 were inoculated into 6-well plates for culture, and ADM with a final concentration of 0.05 μg / ml was added the next day, and the medium was changed every 2-3 days, and the concentration of ADM was gradually increased at the same time; After 3 times, a large number of cells will die, and a small amount of cells can still be adhered to the wall. Continue to gradually increase the concentration of ADM until the remaining adherent cells form a single cell clone; when the cells form a large clone, digest the cells with trypsin, Disperse evenly, and continue to add ADM induction until the cells can be normally passaged, frozen and recovered in ADM wit...

Embodiment 3

[0068] Identification of multidrug resistant cell lines

[0069] Sensitive cells and drug-resistant cells were inoculated in 96-well plates at a cell density of 5×10 4 a / ml;

[0070] Dosing on the next day, the concentration gradient of doxorubicin: 30, 3, 0.3, 0.03, 0.003μg / ml; the concentration gradient of vincristine: 10, 1, 0.1, 0.01, 0.001μg / ml; the concentration of paclitaxel Gradient: 10, 1, 0.1, 0.01, 0.001 μg / ml; 5-FU concentration gradient: 10, 1, 0.1, 0.01, 0.001 μg / ml, drugs were doubled with DMEM medium containing 3% FBS Ratio dilution, the negative group was added with DMEM medium containing 3% FBS, each group was set up with 3 replicate holes, and the volume of administration was 100 μl / well; the cells were treated with 5% CO 2 After continuing to culture in a 37°C incubator for 44 hours, add 20 μl MTT (5 mg / ml) to each well, and continue to culture for 4 hours; discard the supernatant, add 100 μl DMSO to each well, shake on a microplate reader for 600 s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of diosgenin and derivative thereof for preparing tumor chemotherapy sensitization medicines.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of a class of compounds, diosgenin and derivatives thereof, in the preparation of tumor chemotherapeutic sensitization drugs. Background technique [0002] During the course of chemotherapy, tumor cells will develop drug resistance to a large class of drugs that have no correlation in structure and function. This phenomenon is called "multidrug resistance" (MDR). The acquisition of sex is closely related to the expression of various ATP-Binding cassette (ABC) carrier proteins on the cell surface. In human chromosomes, there are about 50 kinds of ABC carrier genes, among which the P-sugar protein encoded by the MDR1 gene Proteins (P-glycoprotein, P-gp or P170) mediate drug resistance most widely in tumor cells (Michihiko Kuwano, et al. Cancer Sci. 2003, 94(1): 9-14; Ulrike Stein, et al. J. Biol. Chem., 2001, 276(30): 28562-28569.). Two mechanisms are cu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/58A61P35/00
Inventor 鲍永利李玉新郑丽华乌垠
Owner NORTHEAST NORMAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap